BN
Brookfield Corp
$42.26
▼ 0.3%Updated Today 3:42 PM ET
BN at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 26/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 3.4% over the last 12 months
Market Cap
$97.01B
P/E
72.61x
Forward P/E (est.)
51.86x
ROE
2.8%
Revenue Growth
-6.6%
EPS Growth
118.0%
Profit Margin
1.8%
FCF Yield
15.1%
Debt / Equity
5.69x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
0.6%
Implied Growth (rev. DCF)
—
Rating Score
26/100
Brookfield Corp (BN) is a large-cap company in the Financial Services industry, part of the Financials sector of the S&P 500, with a market value around $97.01B.
In its latest reported year it generated about $75.10B in revenue and $1.31B in net profit.
Our model rates BN Weak (26/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BN trades near $42.26, below its 50-day average ($44.91) and 200-day average ($44.96). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 43 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. BN's is $1.05 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BN found buyers near $41.90 (support) and sellers near $46.50 (resistance); its 52-week range is $37.93–$49.57. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
-0.2%
Revenue moved from $40.79B in 2017 to $75.10B in 2025, a 7.9% compound annual growth rate. The most recent year declined 6.6% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
37.7%
Operating Margin
6.9%
Net Margin
1.7%
ROE
2.8%
Brookfield Corp keeps about 1.8% of each sales dollar as net profit, with a 37.7% gross margin and 6.9% operating margin. Return on equity is 2.8%. Thin margins leave less cushion if costs rise.
Total Debt
$13.80B
Net Debt
-$2.44B
Net cash position
Net Debt / EBITDA
—
Debt / Equity
5.69x
Leverage: debt-to-equity is 5.7x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $13.80B of total debt against $16.24B of cash.
Operating CF
$10.96B
Free Cash Flow
-$3.79B
FCF Margin
-5.1%
In the latest year Brookfield Corp produced about $10.96B of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about 15.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Dividend yield
0.6%
Per share (latest FY)
$0.24
Total paid (latest FY)
$719.00M
History on record
9 years
free cash flow was negative in the latest year — the dividend is being financed
55% of net income paid out
total dividends increased 2 years in a row
payout was cut at least once in the last 9 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
72.61x
P/S
1.29x
P/B
2.37x
EV / EBITDA
—
BN trades at 72.6x trailing earnings (about 51.9x on estimated forward earnings), 1.3x sales, and 2.4x book value. That is a rich multiple that prices in a lot of future growth.
Where BN sits versus its Financials sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 141 Financials companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How BN stacks up against its Financials peers — valuation, profitability, and growth versus the sector median.
In the Financials sector (289 S&P 500 companies), BN ranks #135 of 289 by our overall rating. It trades at a premium versus the sector on earnings (72.6x P/E vs. 15.3x median) with a lower return on equity (2.8% vs. 13.6%) and slower revenue growth (-6.6% vs. 15.9%).
P/E vs sector
72.6x
median 15.3x
ROE vs sector
2.8%
median 13.6%
Growth vs sector
-6.6%
median 15.9%
Sector rank
#135
of 289 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Financials companies by sub-industry and size. Sector median is across all 289 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $42.26 today · expected CAGR 3% – 14%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $77.35B | $79.67B | $82.06B | $84.53B | $87.06B |
| Net income | $2.32B | $2.39B | $2.46B | $2.54B | $2.61B |
| EPS | $1.01 | $1.04 | $1.07 | $1.10 | $1.14 |
| Share price (low) | $44.48 | $45.82 | $47.19 | $48.61 | $50.07 |
| Share price (high) | $73.80 | $76.01 | $78.29 | $80.64 | $83.06 |
| CAGR (low–high) | 5% / 75% | 4% / 34% | 4% / 23% | 4% / 18% | 3% / 14% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BN:
- Healthy free-cash-flow yield (~15.1%) funds buybacks and dividends.
- As an established S&P 500 member in Financials, it brings scale and a long operating history.
The case against BN:
- Revenue growth is slow/negative (-6.6%), limiting the upside engine.
- Thin net margins (1.8%) leave little room for error.
- Elevated leverage (debt/equity 5.7x) adds financial risk.
- A rich 72.6x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (26/100).
Valuation risk — at 72.6x earnings, disappointing results could compress the multiple.
Balance-sheet risk — debt/equity of 5.7x magnifies the impact of higher rates or weaker earnings.
Growth risk — sluggish revenue (-6.6%) leaves little margin for execution missteps.
Margin risk — thin profitability (1.8%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Brookfield Corp is a large-cap financials business with shrinking revenue, with modest profitability, and a heavier debt load to watch. It trades at 72.6x earnings, which our model scores Weak (26/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 20 Wall Street analysts covering BN recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+6 pts of buy ratings).
Latest SEC Filings
BN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
BN — frequently asked questions
Is BN a good stock to buy?
We don't give buy or sell advice. Our model rates Brookfield Corp Weak (26/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is BN's rating on The Stocks School?
Brookfield Corp currently scores 26/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does BN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Brookfield Corp's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for BN calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this BN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell BN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.